October 19, 2023 Off By Dino Mustafić

SOPHiA genetics with with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca have entered a collaboration to work on providing inclusive access to comprehensive cancer testing worldwide.

The partnership will provide MSK’s proprietary liquid biopsy and solid tumor cancer tests – MSK-ACCESS and MSK-IMPACT – to organizations via the decentralized, technology-agnostic SOPHiA DDM Platform. This offering will be rapidly deployed by SOPHiA GENETICS with support from AstraZeneca’s global footprint.

Jurgi Camblong, PhD., CEO and Co-founder, SOPHiA GENETICS said that the power of a decentralized network like the SOPHiA DDM Platform is that diverse data inputs are continuously added to the network to fuel and teach our artificial intelligence algorithms, helping to produce stronger data outputs each time. He said that the diverse data that will be unlocked through the partnership between SOPHiA GENETICS, AstraZeneca, and MSK will undoubtedly contribute to the collective intelligence needed on a global scale to revolutionize the future of cancer research and treatment.

Anaeze Offodile II, Chief Strategy Officer at MSK said: “MSK is excited to collaborate with SOPHiA GENETICS and AstraZeneca to bring our advanced genomic testing to new populations. We believe that this collaboration will enable patients from around the world to better understand the genomic profile of their cancer. Expanding this to a global population generates a more diverse data set to help develop treatments that could benefit different and often underserved populations.”

Kristina Rodnikova, Head of Global Oncology Diagnostics, AstraZeneca, said: “While cancer continues to be a leading cause of death worldwide, we know that a key barrier for cancer patients and their physicians is a lack of access to high-quality comprehensive genomic testing. Broad access to quality testing can vastly improve cancer diagnosis and physicians’ treatment decisions. We believe that our collaboration with MSK and SOPHiA GENETICS will provide physicians and patients with the reliable data that they need to better diagnose their disease.”